Home / JCRRF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does JCRRF make money? Does JCRRF have pricing power? What's the Earnings Whisper? Will JCRRF profit more as the business scales? What is JCRRF's management track record? Is JCRRF's current price justified?

JCR Pharmaceuticals Co., Ltd.

$3.33 -$1.42 (-29.89%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$3.33

Day Range

$3.32$3.33

Year Range

$3.15$4.75

Market Cap

406.32M

AVG Volume

669

Trailing/Forward PE

77.23/1.05

PEG ratio

438.23

Dividend Yield

3.85%

Next Earnings Date

2026-10-28

Primary Exchange

Other OTC

Revenue (JPY)

JCRRF Revenue (JPY) by year
Period	Revenue (JPY)
2026	32.06B
2025	33.07B
2024	42.87B
2023	34.34B
2022	51.08B
2021	30.09B
2020	24.78B
2019	23.16B
2018	20.59B
2017	18.09B

Net Income (JPY)

JCRRF Net Income (JPY) by year
Period	Net Income (JPY)
2026	2.21B
2025	-4.76B
2024	5.51B
2023	3.77B
2022	14.51B
2021	6.89B
2020	2.68B
2019	3.71B
2018	3.07B
2017	1.86B

Operating Income (JPY)

JCRRF Operating Income (JPY) by year
Period	Operating Income (JPY)
2026	1.11B
2025	-6.86B
2024	7.53B
2023	4.97B
2022	19.93B
2021	8.27B
2020	3.24B
2019	4.97B
2018	3.78B
2017	2.36B

EBITDA (JPY)

JCRRF EBITDA (JPY) by year
Period	EBITDA (JPY)
2026	5.95B
2025	-3.3B
2024	10.72B
2023	7.45B
2022	22.37B
2021	10.18B
2020	4.88B
2019	5.11B
2018	3.92B
2017	2.52B

Cash Flows (JPY)

JCRRF Cash Flows (JPY) by year
Period	Cash Flows (JPY)
2026	0
2025	0
2024	4.54B
2023	3.06B
2022	0
2021	0
2020	0
2019	0
2018	0
2017	0

EPS (JPY)

JCRRF EPS (JPY) by year
Period	EPS (JPY)
2026	18.14
2025	-38.89
2024	43.92
2023	30.24
2022	116.8
2021	55.53
2020	21.59
2019	30
2018	24.53
2017	14.66

Expenses (JPY)

JCRRF Expenses (JPY) by year
Period	Expenses (JPY)
2026	29.81B
2025	41.79B
2024	28.89B
2023	20.48B
2022	20.69B
2021	16.05B
2020	18.43B
2019	13.88B
2018	13.12B
2017	12.37B

Cash & Debt (JPY)

JCRRF Cash & Debt (JPY) by year
Period	Cash & Debt (JPY)
2026	14.1B
2025	13.2B
2024	18.76B
2023	13.28B
2022	30.98B
2021	26.26B
2020	11.19B
2019	8.5B
2018	6.11B
2017	5.81B

Debt ratios

JCRRF Debt ratios by year
Period	Debt ratios
2026	1.93
2025	0.67
2024	0.09
2023	0.21
2022	-0.3
2021	-0.34
2020	-0.15
2019	-0.2

Margins

JCRRF Margins by year
Period	Margins
2026	75.26%
2025	65.09%
2024	72.9%
2023	74.13%
2022	79.52%
2021	74.03%
2020	68.12%
2019	71.65%
2018	70.24%
2017	68.31%

Return on Capital

JCRRF Return on Capital by year
Period	Return on Capital
2026	4.65%
2025	-10.11%
2024	9.75%
2023	7.2%
2022	28.4%
2021	17.88%
2020	8.22%
2019	12.03%
2018	11.15%
2017	6.75%

Shares Outstanding

JCRRF Shares Outstanding by year
Period	Shares Outstanding
2026	122M
2025	122.04M
2024	125.74M
2023	124.78M
2022	123.77M
2021	123.61M
2020	123.32M
2019	123.18M
2018	123.02M
2017	126.3M

Dividends (JPY)

JCRRF Dividends (JPY) by year
Period	Dividends (JPY)
2027	0.07
2026	0.13
2025	0.13
2024	0.14
2023	0.14
2022	0.17
2021	0.16
2020	0.08
2019	0.07
2018	0.06

Book Value Per Share (JPY)

JCRRF Book Value Per Share (JPY) by year
Period	Book Value Per Share (JPY)
2026	390.64
2025	385.46
2024	449.14
2023	420.05
2022	412.76
2021	311.88
2020	264.18
2019	250.61
2018	223.76
2017	218.42

Total Assets (JPY)

JCRRF Total Assets (JPY) by year
Period	Total Assets (JPY)
2026	109.24B
2025	104.86B
2024	102.23B
2023	94.94B
2022	97.13B
2021	73.78B
2020	47.77B
2019	42.52B
2018	38.4B
2017	36.39B

PE Ratio

JCRRF PE Ratio by year
Period	PE Ratio
Sep 26	28.26
Sep 26	28.66
Aug 26	29.38
Aug 26	29.09
Aug 26	29.15
Aug 26	28.86
Jul 26	28.72
Jul 26	29.88
Jul 26	29.62
Jul 26	29.49
Jul 26	29.39
Dec 24	21.96
Dec 24	21.76
Dec 24	21.37
Dec 24	20.87
Nov 24	20.83
Nov 24	21.53
Nov 24	21.47
Nov 24	21.23
Nov 24	21.28
Oct 24	21.18
Oct 24	20.8
Oct 24	20.75
Oct 24	20.69
Sep 24	15.25
Sep 24	15.43
Sep 24	15.1
Sep 24	15.26
Aug 24	14.34
Aug 24	14.17
Aug 24	14.48
Aug 24	14.39
Aug 24	14.38
Jul 24	15.09
Jul 24	15.45
Jul 24	18.82
Jul 24	19.16
Jun 24	19.53
Jun 24	19.4
Jun 24	19.11
Jun 24	19.03
May 24	19.09
May 24	19.06
May 24	18.9
May 24	18.91
May 24	18.57
Apr 24	19.22
Apr 24	18.77
Apr 24	18.6
Apr 24	31.88
Mar 24	21.18
Mar 24	21.19
Mar 24	20.85
Feb 24	21.06
Feb 24	21.06
Feb 24	21.01
Feb 24	20.88
Oct 23	42.62
Oct 23	42.04
Oct 23	42.11
Oct 23	42.03
Oct 23	41.94
Sep 23	46.93
Sep 23	46.48
Sep 23	46.31
Sep 23	46.29
Sep 23	45.81
Aug 23	45.85
Aug 23	45.54
Aug 23	45.4
Aug 23	44.38
Jul 23	44.22
Jul 23	44.52
Jul 23	43.54
Jul 23	44.6
Jun 23	45.29
Jun 23	33.01
Jun 23	36.94
Jun 23	36.29
Jun 23	36.44
May 23	36.62
May 23	35.92
May 23	35.35
May 23	35.11
Apr 23	35.49
Apr 23	34.93
Apr 23	34.83
Apr 23	34.32
Mar 23	33.41
Mar 23	27.06
Mar 23	27.29
Mar 23	27.96
Mar 23	28.11
Feb 23	33.63
Feb 23	33.05
Feb 23	32.38
Feb 23	32.32
Jan 23	49.69
Jan 23	49.61
Jan 23	48.96

Free Cash Flow Yield

JCRRF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	0%
Sep 26	0%
Aug 26	0%
Aug 26	0%
Aug 26	0%
Aug 26	0%
Jul 26	0%
Jul 26	0%
Jul 26	0%
Jul 26	0%
Jul 26	0%
Jun 26	0%
Jun 26	0%
Jun 26	0%
Jun 26	0%
May 26	0%
May 26	0%
May 26	0%
May 26	0%
May 26	0%
Apr 26	0%
Apr 26	0%
Apr 26	0%
Apr 26	0%
Mar 26	0%
Mar 26	0%
Mar 26	0%
Mar 26	0%
Feb 26	0%
Feb 26	0%
Feb 26	0%
Feb 26	0%
Jan 26	0%
Jan 26	0%
Jan 26	0%
Jan 26	0%
Jan 26	0%
Dec 25	0%
Dec 25	0%
Dec 25	0%
Dec 25	0%
Nov 25	0%
Nov 25	0%
Nov 25	0%
Nov 25	0%
Oct 25	0%
Oct 25	0%
Oct 25	0%
Oct 25	0%
Oct 25	0%
Sep 25	0%
Sep 25	0%
Sep 25	0%
Sep 25	0%
Aug 25	0%
Aug 25	0%
Aug 25	0%
Aug 25	0%
Aug 25	0%
Jul 25	0%
Jul 25	0%
Jul 25	0%
Jul 25	0%
Jun 25	0%
Jun 25	0%
Jun 25	0%
Jun 25	0%
May 25	0%
May 25	0%
May 25	0%
May 25	0%
May 25	0%
Apr 25	0%
Apr 25	0%
Apr 25	0%
Apr 25	0%
Mar 25	2.19%
Mar 25	2.2%
Mar 25	2.21%
Mar 25	2.22%
Feb 25	2.18%
Feb 25	2.2%
Feb 25	2.15%
Feb 25	2.17%
Jan 25	2.12%
Jan 25	2.1%
Jan 25	2.1%
Jan 25	2.08%
Jan 25	2.09%
Dec 24	3.91%
Dec 24	3.95%
Dec 24	4.02%
Dec 24	4.12%
Nov 24	4.12%
Nov 24	3.99%
Nov 24	4%
Nov 24	4.04%
Nov 24	4.04%
Oct 24	4.05%
Oct 24	4.13%

Price to Sales

JCRRF Price to Sales by year
Period	Price to Sales
Sep 26	1.95
Sep 26	1.98
Aug 26	2.03
Aug 26	2.01
Aug 26	2.01
Aug 26	1.99
Jul 26	1.98
Jul 26	2.06
Jul 26	2.04
Jul 26	2.04
Jul 26	2.03
Jun 26	2.12
Jun 26	2.11
Jun 26	2.1
Jun 26	2.1
May 26	2.77
May 26	2.77
May 26	2.76
May 26	2.73
May 26	2.73
Apr 26	2.77
Apr 26	2.76
Apr 26	2.77
Apr 26	2.78
Mar 26	2.77
Mar 26	2.75
Mar 26	2.76
Mar 26	2.72
Feb 26	2.69
Feb 26	2.68
Feb 26	2.63
Feb 26	2.71
Jan 26	2.67
Jan 26	3.06
Jan 26	3.11
Jan 26	3.1
Jan 26	3.08
Dec 25	3.43
Dec 25	3.46
Dec 25	3.42
Dec 25	3.41
Nov 25	3.43
Nov 25	3.43
Nov 25	3.39
Nov 25	3.37
Oct 25	3.38
Oct 25	3.35
Oct 25	3.12
Oct 25	3.13
Oct 25	3.06
Sep 25	2.34
Sep 25	2.32
Sep 25	2.32
Sep 25	2.72
Aug 25	2.71
Aug 25	2.71
Aug 25	2.71
Aug 25	2.73
Aug 25	2.72
Jul 25	2.72
Jul 25	2.75
Jul 25	2.06
Jul 25	2.02
Jun 25	1.9
Jun 25	1.92
Jun 25	2.18
Jun 25	2.3
May 25	2.29
May 25	2.27
May 25	2.31
May 25	2.31
May 25	2.3
Apr 25	2.28
Apr 25	2.26
Apr 25	2.28
Apr 25	2.33
Mar 25	2.42
Mar 25	2.42
Mar 25	2.4
Mar 25	2.4
Feb 25	2.44
Feb 25	2.41
Feb 25	2.46
Feb 25	2.45
Jan 25	2.51
Jan 25	2.52
Jan 25	2.53
Jan 25	2.55
Jan 25	2.54
Dec 24	2.24
Dec 24	2.22
Dec 24	2.18
Dec 24	2.13
Nov 24	2.12
Nov 24	2.19
Nov 24	2.19
Nov 24	2.16
Nov 24	2.17
Oct 24	2.16
Oct 24	2.12

EV/EBITDA

JCRRF EV/EBITDA by year
Period	EV/EBITDA
Sep 26	17.26
Sep 26	17.41
Aug 26	17.68
Aug 26	17.57
Aug 26	17.6
Aug 26	17.49
Jul 26	17.44
Jul 26	17.87
Jul 26	17.77
Jul 26	17.72
Jul 26	17.68
Jun 26	523.96
Jun 26	523.3
Jun 26	520.92
Jun 26	521.09
May 26	624.92
May 26	624.77
May 26	623.54
May 26	617.96
May 26	618.96
Apr 26	625.1
Apr 26	623.19
Apr 26	624.95
Apr 26	625.89
Jun 25	34.1
Jun 25	34.37
Jun 25	38.15
Jun 25	39.83
May 25	39.65
May 25	39.31
May 25	40.01
May 25	39.95
May 25	39.86
Apr 25	39.56
Apr 25	39.28
Apr 25	39.51
Apr 25	40.3
Mar 25	26.89
Mar 25	26.8
Mar 25	26.69
Mar 25	26.6
Feb 25	27.01
Feb 25	26.79
Feb 25	27.28
Feb 25	27.14
Jan 25	27.74
Jan 25	27.87
Jan 25	27.92
Jan 25	28.15
Jan 25	28.08
Dec 24	10.66
Dec 24	10.57
Dec 24	10.4
Dec 24	10.18
Nov 24	10.16
Nov 24	10.47
Nov 24	10.44
Nov 24	10.34
Nov 24	10.36
Oct 24	10.32
Oct 24	10.15
Oct 24	10.12
Oct 24	10.1
Sep 24	8.26
Sep 24	8.36
Sep 24	8.19
Sep 24	8.27
Aug 24	7.8
Aug 24	7.71
Aug 24	7.87
Aug 24	7.82
Aug 24	7.81
Jul 24	8.18
Jul 24	8.36
Jul 24	10.09
Jul 24	10.27
Jun 24	10.21
Jun 24	10.14
Jun 24	10
Jun 24	9.96
May 24	9.99
May 24	9.97
May 24	9.89
May 24	9.9
May 24	9.73
Apr 24	10.05
Apr 24	9.83
Apr 24	9.74
Apr 24	16.37
Mar 24	13.55
Mar 24	13.56
Mar 24	13.35
Feb 24	13.48
Feb 24	13.48
Feb 24	13.45
Feb 24	13.37
Oct 23	24.01
Oct 23	23.69
Oct 23	23.73
Oct 23	23.69

Price/Operating Cashflow

JCRRF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Mar 25	45.65
Mar 25	45.49
Mar 25	45.29
Mar 25	45.11
Feb 25	45.9
Feb 25	45.47
Feb 25	46.41
Feb 25	46.13
Jan 25	47.28
Jan 25	47.52
Jan 25	47.62
Jan 25	48.05
Jan 25	47.92
Dec 24	25.57
Dec 24	25.34
Dec 24	24.89
Dec 24	24.3
Nov 24	24.26
Nov 24	25.07
Nov 24	25
Nov 24	24.72
Nov 24	24.78
Oct 24	24.67
Oct 24	24.22
Oct 24	24.16
Oct 24	24.09
Sep 24	18.5
Sep 24	18.72
Sep 24	18.32
Sep 24	18.51
Aug 24	17.4
Aug 24	17.18
Aug 24	17.56
Aug 24	17.45
Aug 24	17.44
Jul 24	18.3
Jul 24	18.73
Jul 24	22.82
Jul 24	23.23
Jun 24	18.6
Jun 24	18.48
Jun 24	18.2
Jun 24	18.13
May 24	18.19
May 24	18.16
May 24	18
May 24	18.02
May 24	17.69
Apr 24	18.31
Apr 24	17.88
Apr 24	17.72
Apr 24	30.37
Mar 24	35.89
Mar 24	35.9
Mar 24	35.33
Feb 24	35.69
Feb 24	35.68
Feb 24	35.61
Feb 24	35.39
Oct 23	41.91
Oct 23	41.34
Oct 23	41.4
Oct 23	41.33
Oct 23	41.24
Sep 23	46.15
Sep 23	57.29
Sep 23	57.08
Sep 23	57.06
Sep 23	56.47
Aug 23	56.52
Aug 23	56.13
Aug 23	55.97
Aug 23	54.71
Jul 23	54.5
Jul 23	54.88
Jul 23	53.67
Jul 23	54.98
Jun 23	55.83
Jun 23	86.36
Jun 23	96.66
Jun 23	94.95
Jun 23	95.33
May 23	95.81
May 23	93.97
May 23	92.49
May 23	91.86
Apr 23	92.86
Apr 23	91.37
Apr 23	91.12
Apr 23	89.78
Mar 23	87.41
Mar 23	173.57
Mar 23	175.05
Mar 23	179.34
Mar 23	180.33
Feb 23	215.71
Feb 23	212.03
Feb 23	207.73
Feb 23	207.34
Jan 23	318.76

Price to Book

JCRRF Price to Book by year
Period	Price to Book
Sep 26	1.31
Sep 26	1.33
Aug 26	1.36
Aug 26	1.35
Aug 26	1.35
Aug 26	1.34
Jul 26	1.33
Jul 26	1.39
Jul 26	1.38
Jul 26	1.37
Jul 26	1.37
Jun 26	1.32
Jun 26	1.32
Jun 26	1.31
Jun 26	1.31
May 26	1.73
May 26	1.73
May 26	1.73
May 26	1.7
May 26	1.71
Apr 26	1.73
Apr 26	1.72
Apr 26	1.73
Apr 26	1.73
Mar 26	248.34
Mar 26	246.72
Mar 26	247.49
Mar 26	244.47
Feb 26	241.76
Feb 26	240.25
Feb 26	236.53
Feb 26	243.59
Jan 26	239.82
Jan 26	274.93
Jan 26	279.03
Jan 26	278.77
Jan 26	276.8
Dec 25	1.84
Dec 25	1.86
Dec 25	1.83
Dec 25	1.83
Nov 25	1.84
Nov 25	1.84
Nov 25	1.82
Nov 25	1.8
Oct 25	1.81
Oct 25	1.8
Oct 25	1.67
Oct 25	1.68
Oct 25	1.64
Sep 25	1.65
Sep 25	1.63
Sep 25	1.63
Sep 25	1.91
Aug 25	1.91
Aug 25	1.91
Aug 25	1.91
Aug 25	1.92
Aug 25	1.91
Jul 25	1.92
Jul 25	1.93
Jul 25	1.45
Jul 25	1.42
Jun 25	1.26
Jun 25	1.27
Jun 25	1.44
Jun 25	1.52
May 25	1.51
May 25	1.5
May 25	1.53
May 25	1.53
May 25	1.52
Apr 25	1.51
Apr 25	1.5
Apr 25	1.51
Apr 25	1.54
Mar 25	1.5
Mar 25	1.49
Mar 25	1.49
Mar 25	1.48
Feb 25	1.51
Feb 25	1.49
Feb 25	1.52
Feb 25	1.51
Jan 25	1.55
Jan 25	1.56
Jan 25	1.56
Jan 25	1.58
Jan 25	1.57
Dec 24	1.62
Dec 24	1.6
Dec 24	1.57
Dec 24	1.54
Nov 24	1.53
Nov 24	1.59
Nov 24	1.58
Nov 24	1.56
Nov 24	1.57
Oct 24	1.56
Oct 24	1.53

No video analysis for this stock yet. Request one from our team.

News: JCRRF

businesswire.com · 11 Sep 2026

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

TOKYO & HYOGO, Japan--(BUSINESS WIRE)--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.

businesswire.com · 21 Jul 2026

JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.

businesswire.com · 17 Jun 2026

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®